Skip to main content
TipRanks
Go Ultimate75% OFF

Dianthus Therapeutics (87E) Ownership - Who Owns Dianthus Therapeutics?

0 Followers

Dianthus Therapeutics (87E) Ownership Overview

  • 0.15% Insiders
  • 36.56% Mutual Funds
  • 16.84% Other Institutional Investors
  • 15.70% ETFs
  • 30.75% Public Companies and Individual Investors

The ownership structure of Dianthus Therapeutics (DE:87E) stock is a mix of institutional, retail, and individual investors. Approximately 69.10% of the company’s stock is owned by Institutional Investors, 0.15% is owned by Insiders, and 30.75% is owned by Public Companies and Individual Investors.

Institutional holdings as of (latest 13F reporting period).

Recent Insider Trading Activity

Recent Insider Trading Activity
DateNameActivityValue
Aug 06, 2026Garcia Marino$13,619,611

Recent Hedge Fund Trading Activity

Recent Hedge Fund Trading Activity
DateFirmActivityValue
Dec 31, 2025Antipodes Partners Ltd€18,915
Dec 31, 2025Fisher Asset Management Llc€574,797
Dec 31, 2025Woodline Partners Lp€8,781,315
Dec 31, 2025Iron Triangle Partners Lp€9,508,383

Top Shareholders

DE:87E top shareholders
Holder# of SharesType% HoldingValue
BlackRock, Inc.4,389,604Institution7.80%377,839,554
Vanguard3,472,878Institution6.17%298,931,447
Peter Kolchinsky2,611,733Institution4.64%224,807,530
Peter Harwin2,537,191Institution4.51%218,391,253
Fidelity Mt. Vernon Street Trust2,437,098Institution4.33%209,775,647
Vanguard Index Funds2,107,558Institution3.74%181,410,162
Ishares1,984,689Institution3.52%170,834,090
Spdr1,580,054Institution2.81%136,004,728
Vanguard Specialized Funds1,503,955Institution2.67%129,454,431
T. Rowe Price Small-cap Stock Fund, Inc.1,155,511Institution2.05%99,461,765

Top Mutual Fund Holders

DE:87E top mutual fund holders
Holder# of SharesType% HoldingValue
Fidelity Mt. Vernon Street Trust2,437,098Institution4.33%209,775,647
Vanguard Index Funds2,107,558Institution3.74%181,410,162
Vanguard Specialized Funds1,503,955Institution2.67%129,454,431
T. Rowe Price Small-cap Stock Fund, Inc.1,155,511Institution2.05%99,461,765
Fidelity Securities Fund1,081,453Institution1.92%93,087,148
Fidelity Advisor Series Vii893,319Institution1.59%76,893,326
Fidelity Select Portfolios870,518Institution1.55%74,930,707
T. Rowe Price Equity Funds, Inc.683,486Institution1.21%58,831,741
Fidelity Salem Street Trust680,391Institution1.21%58,565,336
T. Rowe Price New Horizons Fund, Inc.673,057Institution1.20%57,934,054

FAQ

Who Owns Dianthus Therapeutics (DE:87E)?
According to the latest TipRanks data (13F holdings as of December 31, 2025), approximately 69.10% of the company's stock is held by institutional investors, 0.15% is held by insiders, and 30.75% is held by public companies and individual investors.
What percentage of Dianthus Therapeutics (DE:87E) stock is held by institutional investors?
According to the latest TipRanks data (13F holdings as of December 31, 2025), approximately 69.10% of Dianthus Therapeutics (DE:87E) stock is held by institutional investors: 36.56% by mutual funds, 15.70% by ETFs and 16.84% by other institutional investors.
What percentage of Dianthus Therapeutics (DE:87E) stock is held by retail investors?
According to the latest TipRanks data (13F holdings as of December 31, 2025), approximately 30.75% of Dianthus Therapeutics (DE:87E) stock is held by public companies and individual investors.
Who owns the most shares of Dianthus Therapeutics (DE:87E)?
BlackRock, Inc. owns the most shares of Dianthus Therapeutics (DE:87E).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.